Emerging Roles of GluN3B NMDA Receptor Subunit in the Central Nervous System.

Yuerou Huang, Junyi Xie, Jiamin Chen, Siman Guo, Yuan Li, Fang Liu

Abstract readReview

In one paragraph

Review in Neuroscience bulletin, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yuerou Huang *Institute of Mental Health and Drug Discovery, Oujiang Laboratory (Zhejiang Lab for Regenerative Medicine, Vision and Brain Health), School of Psychiatry, Wenzhou Medical University, Wenzhou, 325000, China.

Junyi Xie *Brain Health Institute, National Center for Mental Disorders, Shanghai Mental Health Center, Shanghai Jiaotong University School of Medicine, Shanghai, 200030, China.

Jiamin ChenInstitute of Mental Health and Drug Discovery, Oujiang Laboratory (Zhejiang Lab for Regenerative Medicine, Vision and Brain Health), School of Psychiatry, Wenzhou Medical University, Wenzhou, 325000, China.

Siman GuoInstitute of Mental Health and Drug Discovery, Oujiang Laboratory (Zhejiang Lab for Regenerative Medicine, Vision and Brain Health), School of Psychiatry, Wenzhou Medical University, Wenzhou, 325000, China.

Yuan LiInstitute of Mental Health and Drug Discovery, Oujiang Laboratory (Zhejiang Lab for Regenerative Medicine, Vision and Brain Health), School of Psychiatry, Wenzhou Medical University, Wenzhou, 325000, China. zmd2012spring@126.com.

Fang LiuInstitute of Mental Health and Drug Discovery, Oujiang Laboratory (Zhejiang Lab for Regenerative Medicine, Vision and Brain Health), School of Psychiatry, Wenzhou Medical University, Wenzhou, 325000, China. fang.liu@camh.ca.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

GluN3B is the most recently identified subunit of N-methyl-d-aspartate receptors (NMDARs), and gradually it has been found that it may be involved in regulating the development of central nervous system (CNS)-related diseases. Compared with the traditional NMDARs containing only GluN1 and GluN2 subunits, non-classical NMDARs with GluN3 have non-conventional biophysical, trafficking, and signaling properties. As a negative regulatory subunit that diminishes or inhibits classical NMDARs' functions, GluN3B plays important roles in synaptic plasticity and neuronal survival, and may be associated with CNS disorders such as schizophrenia and substance use disorders. However, the number and depth of studies on how GluN3B is involved in the regulation of related diseases are very limited. This review summarizes the expression and physiological characterization of GluN3B-NMDARs and provides an overview of their emerging roles in psychiatric and neuropsychiatric disorders, aiming to provide a basis for understanding disease mechanisms and developing novel therapeutic targets.

Indexed as

Central Nervous SystemReceptors, N-Methyl-D-AspartateAnimalsHumansNeuronal PlasticityReceptors, N-Methyl-D-AspartateBiophysical propertiesGluN3BGrin3bNMDA receptorsPharmacological characteristicsPsychiatric disorders

Identifiers

PMID41139355

DOI10.1007/s12264-025-01523-z

PMCPMC12950151

What Socratic holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.